Meditech ---Eine Granate fürs Depot ! - 500 Beiträge pro Seite

[BrauchGeld]

Hallo

Für mich als Biotechfan ist diese Aktie ein muss,Meditech erfüllt alle meine erwartungen u.a gutes Management aussichtsreiche Produkte und eine übertriebene Unterbewertung.
Bei Erfolg sind 1000% immer noch zuwenig und die aussichten sind nicht gerade schlecht.


Homepage:
http://www.mrl.com.au/

Pipeline:
http://www.mrl.com.au/index.php?type=1&id=323

Aegis Report Feb.2006:
http://www.mrl.com.au/downloads/Aegis_Quarterly_Report_-_Feb…

Southern Cross Analyse:
http://www.mrl.com.au/downloads/Southern_Cross_Equities_04.1…

Meditech (MTR.AX)
Marktkap:13 mioA$-----8,09 mio€
Kurs:0,097 A$ ----- ASX
Kurs:0,062 € ----- Berlin


Meditech is working on a cancer drug delivery technology called HyACT, which uses hyaluronic
acid, a naturally-occurring carbohydrate, to deliver cancer drugs into tumours and cancer cells;
HyACT has strong supporting data indicating that it can improve both the safety and efficacy of
existing cancer drugs;
HyCAMP, the cancer drug Camptosar delivered by HyACT, is currently the subject of a Phase IIb
trial in colorectal cancer patients. In 2004 a Phase I/IIa trial generated favourable clinical data;
Meditech has attracted the Danish enzymes technology developer Novozymes as a partner in the
development of HyCAMP, with Novozymes partly funding the Phase IIb trial;
From September 2004 Meditech has had a well-regarded CEO in the former Millennium
Pharmaeuticals executive Dr Ian Nisbet. Since his appointment Nisbet has pursued a very commercial
R&D and business development agenda;
HyACT shows potential as a cancer drug delivery platform technology;
Meditech has flagged that before 2005 is out it will be in a position to announce at least one
commercial partnership related to a HyACT product. It’s expected that an Investigational New Drug
application will be filed with the FDA for HyCAMP in the first half of 2006, and that HyCAMP will
complete Phase IIb by mid-2006. We expect that a pivotal Phase III trial will start in 2007.
Our early stage valuation of Meditech, on a fully diluted basis, is 40 cents per share base case and 67
cents optimistic case. Our share price target for the stock is 36 cents, which is a 10% discount to our base case.


----------

The reason why Meditech’s strategy is commercial is that often chemotherapy is only efficacious at doses that are
highly toxic to the patient. Many of the drugs used are tried and tested and have a strong following amongst
oncologists, but they could be made much more effective and/or patient friendly if they could be better targeted to
the site of cancer. Such targeting would allow more cancer cells to be killed with less in the way of toxicity to the
patient. Put another way, many cancer drugs could be made safer as well as more efficacious with the use of
Meditech’s technology.
Meditech is still some years away from having a product on the market, but it has been generating some encouraging
data with applications of the HyACT technology. Proof of concept in man trials in 2002 established that the HyACT
concept worked well. And Meditech’s lead compound is now in an 86-patient Phase IIb trial in colorectal cancer
patients that is scheduled for completion around mid-2006 . Should this trial succeed, the current low market
capitalisation of Meditech will in retrospect look rather inexpensive.
This report looks first at why Meditech is a good company to back from a management perspective. It then considers
Meditech’s technology and its potential applications. And finally we attempt an early stage valuation of the
company, allowing us to arrive at a target price for the stock of 36 cents per share.

[BrauchGeld]

"Meditech’s lead compound is now in an 86-patient Phase IIb trial in colorectal cancer
patients that is scheduled for completion around mid-2006 "

Jeder kann sich dann ausmalen was dann passiert wenn die ergebnisse positiv ausfallen.

[NATALY [VIP]]

Granate fürs Depot

Nach der Explosion der Granate bleibt vom Depot nichts übrig.

[BrauchGeld]

Moin

Meditech steht kurz davor die 0,1A$ zu knacken danach dürfte es ähnlich wie in Okt.05 zugehen(s.Chart).

Kurs:0,099 A$

[BrauchGeld]

Nabend

Hätte ich das nötige kleingeld hätte ich diese Firma direkt übernommen.


1: HyACT™
Target Market: Oncology
Stage: Phase II
Target Date: 3Q06

Meditech is applying its HyACT™ platform to the development of
safer and/or more effective formulations of cytotoxic drugs. In
addition to the products listed below, Meditech is researching
HyACT™ formulations of several other important oncology drugs.

2: HyCAMP™
Target Market: Oncology
Stage: Phase II
Target Date: 3Q06

HyCAMP™ is Meditech’s proprietary formulation of irinotecan with
Hyaluronic Acid (HA), designed to reduce the serious side effects
commonly associated with irinotecan treatment. In collaboration with
Danish-based biotech company Novozymes, Meditech commenced an
86 patient, randomised Phase II clinical study of HyCAMP™ in
metastatic colorectal cancer patients in Q4 2004. In addition,
Meditech has received $2.98 million towards the commercialisation of
HyCAMP™ from the Australian government.

3: HyDOX™ and HyFIVE™
Target Market: Oncology
Stage: Phase I
Target Date: Complete

HyDOX™ is the formulation of doxorubicin with HA. In pre-clinical
testing, HyDOX™ showed a significant reduction in the irreversible
heart damage often associated with prolonged treatment with
doxorubicin, while maintaining a superior therapeutic effect.
HyFIVE™ is the formulation of 5-fluorouracil (5-FU) with HA.

4: HAS2
Target Market: Oncology
Stage: Research
Target Date: 3Q06
Meditech has identified a novel, potential drug target in breast cancer
cells. The enzyme HA synthase 2 (HAS2) is involved in the HA
biosynthetic pathway and early data generated by Meditech suggest
that it might be a suitable target for the development of small
molecule or antibody-based therapies.

------------------
Key Executives
Dr Ian Nisbet (PhD), Chief Executive Officer: Dr Nisbet has been CEO since
September 2004. He has extensive product development and
commercialisation experience in the biotechnology sector based on 25 years`
experience with Millennium Pharmaceuticals Inc., Cambridge, MA and CSL Ltd.

Dr Tracey Brown (BSc, PhD), Chief Scientific Officer: Dr Brown holds an
adjunct position as Associate Professor in the Department of Biochemistry and
Molecular Biology, Monash University. She is an international expert in matrix
biology and has more than 50 scientific publications.

Mr Robert Stewart (LLB(Hons), MBA), Chairman: Mr Stewart is formerly the
National Managing Partner of Minter Ellison and is currently the Chairman of
Melbourne IT Limited, Plantic Limited and CE Bartlett Pty Ltd.

Prof Richard Fox (PhD, MBBS, FRACP), Non-executive Director: Professor Fox
is Professor and Director of the Dept of Clinical Haematology and Medical
Oncology at Royal Melbourne Hospital.

Prof John Papadimitriou (AM, OstJ, BA, MBBS, PhD, MD, FRCPath, FRCPA,
FIBiol), Non-executive Director: Professor Papadimitriou is an Emeritus
Professor in the School of Surgery and Pathology at the University of WA.

Dr Julian Clark (BSc(Hons), PhD), Non-executive Director: Dr Clark is
currently Head of Business Development at the Walter and Eliza Hall Institute
in Melbourne.

[BrauchGeld]

Hallo


Alchemia scheint mein thread zulesen .
Heute wurde ich wieder belohnt danke Alchemia.
Da sich Alchemia auch in meinem Depot befindet bin ich zufrieden mit der übernahme.
Alchemia ist damit noch attraktiver geworden.

Hier die Präsentation dazu:
http://www.alchemia.com.au/investors/announcements/ALC_Medi_…

Australia`s Alchemia to buy Meditech for A$17 mln

Thursday March 9, 2006, 11:40 am



MELBOURNE, March 9 (Reuters) - Australian biotech group Alchemia Ltd. (ASX: ACL.ax) offered A$17.2 million ($12.6 million) worth of its shares to take over Meditech Research Ltd. (ASX: MTR.ax) as it looks to fill a gap in its product pipeline.

Alchemia, which has a synthetic anti-blood clotting drug due to be launched in the United States in 2008 and is in the early stages of developing a new class of antibiotics, said Meditech directors had agreed to accept its offer in the absence of a better proposal.

The bid is at a 41 percent premium to Meditech`s close on Wednesday and about a 9 percent premium to its latest trade on Thursday.

Meditech has a product to treat colorectal cancer patients in clinical trials to test its safety and effectiveness and two cancer treatments that have completed early stage safety trials.

Its products are used to improve existing approved cancer drugs.

"These products complement Alchemia`s early and late stage revenue generating opportunities," Alchemia Chief Executive Tracie Ramsdale said in a statement.

Alchemia is offering one of its shares for every nine Meditech shares, valuing Meditech at A$17.2 million, or a 9.3 percent premium, based on Alchemia`s last trade at A$1.23.

Meditech shares last traded about 29 percent higher at A$0.125.

Alchemia will also provide a short-term loan of up to A$2 million to Meditech during the bid period.

The two groups have agreed on a break fee if the deal does not go ahead.

Besides securing a big premium to its current value, Meditech will gain financial strength and better access to capital by joining with Alchemia, the Brisbane-based group said.

ABN AMRO Morgans is advising Alchemia, while Global Markets Capital Group is advising Meditech.

[BrauchGeld]